{"name":"EyePoint Pharmaceuticals","slug":"eyepoint","ticker":"EYPT","exchange":"NASDAQ","domain":"eyepointpharma.com","description":"EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.","hq":"Watertown, MA","founded":0,"employees":"214","ceo":"Nancy Lurker","sector":"Ophthalmology","stockPrice":14.04,"stockChange":0.47,"stockChangePercent":3.46,"marketCap":"$1.2B","metrics":{"revenue":55000000,"revenueGrowth":161.7,"grossMargin":0,"rdSpend":221039000,"netIncome":-231962000,"cash":45261000,"dividendYield":0,"peRatio":-5.1,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"YUTIQ patent cliff ($14.6M at risk)","drug":"YUTIQ","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AKB-9778 4%","genericName":"AKB-9778 4%","slug":"akb-9778-4","indication":"Other","status":"phase_2"},{"name":"Dexycu","genericName":"Dexycu","slug":"dexycu","indication":"Other","status":"marketed"},{"name":"AKB-9778","genericName":"AKB-9778","slug":"akb-9778","indication":"Other","status":"phase_2"},{"name":"Prednisolone Acetate Ophthalmic","genericName":"Prednisolone Acetate Ophthalmic","slug":"prednisolone-acetate-ophthalmic","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EYP-1901","genericName":"EYP-1901","slug":"eyp-1901","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"AKB-9778 4%","genericName":"AKB-9778 4%","slug":"akb-9778-4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dexycu","genericName":"Dexycu","slug":"dexycu","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AKB-9778","genericName":"AKB-9778","slug":"akb-9778","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EYP-1901","genericName":"EYP-1901","slug":"eyp-1901","phase":"phase_3","mechanism":"EYP-1901 is a sustained-release corticosteroid implant designed to deliver anti-inflammatory therapy directly to the eye.","indications":["Dry eye disease","Anterior uveitis"],"catalyst":""},{"name":"Prednisolone Acetate Ophthalmic","genericName":"Prednisolone Acetate Ophthalmic","slug":"prednisolone-acetate-ophthalmic","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"EyePoint Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with net sales of $14.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"EyePoint Pharmaceuticals Announces Collaboration with Oyster Point Pharma to Develop Sustained-Release Formulation of OC-01","summary":"EyePoint Pharmaceuticals entered into a collaboration with Oyster Point Pharma to develop a sustained-release formulation of OC-01, a treatment for dry eye disease.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"regulatory","headline":"FDA Approves EyePoint Pharmaceuticals' YUTIQ for the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment of the Eye","summary":"The FDA approved YUTIQ, a sustained-release treatment for non-infectious uveitis affecting the posterior segment of the eye.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOaDJKblJ2Y3MycEM5LWt1cm5QWXBkSllland2eVZ5OUp6ZFdRdjVEWWJXakd5a0VlellzZlZYUmJvQXpYMy00XzE2aW8wOGRDSWlVcHp2LW5FdnhkYmI3S1JzWHNrNlBSNTNKZ1lSRHV5NUI3S0o1MFVibl90WWUtaXpJWGRTeWdxTVVMYTllZGZIOHJ0NllqWGhudmo4SmlpMDVSXzdlUFVPXzZ1QkwxdFAxXzdNRU0?oc=5","date":"2026-02-16","type":"pipeline","source":"24/7 Wall St.","summary":"Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year - 24/7 Wall St.","headline":"Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"earnings","source":"simplywall.st","summary":"EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st","headline":"EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQbE9kSmQtYlZKNzJyV1R0MmRJc2ZZa0NWdmdLaDY5czhSdG5lc2VBNENYSkxYRzRtSE5saS05QUdBV0traWUxZmxIZEJLbldIZ0UyelFBT2JsOUdoRmdBUTVMOWkxdVRxTUN1Z1hQUGRFX2EyeGlxM0R4b3FtUzAzQzhaVWZtVnlhem1pOWtkd0FTaFR4SkVRY0VfdWN5czlpaGVIeEw2TmJ5c3RERmFRTE8yemY3LUJuN2h5cThRQWNJOWF1a2dKdXRYejB6VlNNVkVwaVA1Z2p5YllISEw3VGY4SXFmS3dEdzhSdjFwUjdMSjlWQU9qR3hzcnJ5elhNVjZORlBzdkg4eWR4Y3VOcG9xRDgxcjZ0Ul9WclFYSnJuT2hCcTlsTEhVUG9GZF9jZ1M2OG1lV1ZmRXBEZ1E?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pharmaceuticals (ANIP) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pha","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNQnptbzRBNzBLTlhsSVp2NVhGOEJpWnY0SUNLT3Z6OEFDb2JTNFJSelpkU2JuSkdjeXFta2lNNXJSelRqUDZ2Zk9rMTA1cFZ3ODJkVXBSNkhGc1JEY0RhOUxHbnVzNHV1MW5KUFB0TVctY3hEbmxYbTBDQUtYWlpnbUJ4a0lPcC1Kb1RsWVlrcUMtXzY1ZUtUU0pQR0QySS14czR3dFc1WWVvbzltV3owd2N5aTJEdE5L?oc=5","date":"2025-12-22","type":"pipeline","source":"TradingView","summary":"3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - TradingView","headline":"3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOLW91UThQWXA4TDB5N29pZVduNnotc3RNb2txWXMzODRWQW4zTnhYbDZlVDI5WVVrN0N3RFotTzNSSGNxQVQzeFBNRWpRV3RLWEFqOU0zRnpsWGR6RGJTbGtQV0xCQWRaTEFPalhGSUk1LUN1bUo3ald0emp2Q1VYRVl3Q3J3cUhuNVV2OUZBOFZyLW1aZWZrRllwYw?oc=5","date":"2025-11-19","type":"trial","source":"Yahoo Finance","summary":"EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Yahoo Finance","headline":"EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOcVpBdXhvamRtNUJjdGJzNktGMFdnV1NaTkZHeDZhVzJYRFlRRW5CNjNXcVJDM2h2blNIaVc3V3BoV0MzQmU3cTZzZThYdmhpcjFEaXlaNXpWT2dWUWF2SGxRcUloSllzSWREcUJNMmxVZnlKMmVxaTdYTnZWZ0psdFJIUFc1N1g5bjVWWVFxekY?oc=5","date":"2025-11-06","type":"earnings","source":"Yahoo Finance","summary":"EyePoint Pharmaceuticals (EYPT): Forecast 61.3% Revenue Growth Tests Premium Valuation, Ongoing Losses - Yahoo Finance","headline":"EyePoint Pharmaceuticals (EYPT): Forecast 61.3% Revenue Growth Tests Premium Valuation, Ongoing Losses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxORnNTNDlrbXpjU2xrNkVyMy1Cc0JXaXhWWnRYOFplOERkTlBPSzhMcXRlNjFHa0dQLVBfTHVPOVhkMkkxZkNNakZ3TzFDR0s5aEVtQUJzM21EQzB1SUgyZFpqektTcEZ3YkViWnkwT1J0eE1yMWhQazJGSVN3MGQ3QVVvSkw2S19ja0lsT0RyY0hLbWVBVEdGSFJldUVYWEVuai1RMUxVX2ZHZ0ZOUUJVVENuV0JCcE5QQWJPTjRqY2hmbXc?oc=5","date":"2025-10-15","type":"pipeline","source":"TradingView","summary":"EyePoint Pharma falls on pricing $150 mln stock offering - TradingView","headline":"EyePoint Pharma falls on pricing $150 mln stock offering","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-14","type":"deal","source":"simplywall.st","summary":"Pleasing Signs As A Number Of Insiders Buy EyePoint Pharmaceuticals Stock - simplywall.st","headline":"Pleasing Signs As A Number Of Insiders Buy EyePoint Pharmaceuticals Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOVkVMaUZCMGJUX3B0eWZIM3J2QkROWVZaMDlJNG50dGhEN0NQSHN6bmJFOWJ4MTZZdDhwMjZSLWtVcjJ0X05xcEhDYlBBWS10RmE4Y0RvcnVhbGN1MmprS2dFd2h4RTNmQnpjNHVXeTRDUlBla09YLUt1SjMtYVFtOFV5S01pUlptZVBYbDVXeG56bkt5cjhzU2FnZE40bFg0b0E1OGw2TkIyMHk0MlFNbQ?oc=5","date":"2025-06-12","type":"trial","source":"Seeking Alpha","summary":"EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha","headline":"EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026 (NASDAQ:EYPT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOMFZGNUc4SGhiS3NTT1RpMzRMOGoxeXg4WjRjRVU1TnpwM0ZnTVhhczQ1MVdOaTU5V1didnU5TkJUVWdLWjZHZ2Y5ZExuaTFUTWtyamdaUk5fWVFWc3AtUGx0dXBHdWt2UXp0NXZ6R3M1NzFTWjctd25qaXhNazBIWnI4c2E?oc=5","date":"2025-04-02","type":"pipeline","source":"Yahoo Finance","summary":"Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance","headline":"Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation","sentiment":"neutral"}],"patents":[{"drugName":"YUTIQ","drugSlug":"dexamethasone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":14600000}],"drugCount":5,"phaseCounts":{"phase_2":2,"marketed":2,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Regeneron Pharmaceuticals","Allergan"],"therapeuticFocus":["Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":7539000,"revenuePeriod":"2017-06-30","revenueHistory":[{"value":7539000,"period":"2017-06-30"},{"value":701000,"period":"2017-06-30"},{"value":590000,"period":"2017-03-31"},{"value":5971000,"period":"2016-12-31"},{"value":277000,"period":"2016-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":221039000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-231962000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":363996000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":214,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.04,"previousClose":13.57,"fiftyTwoWeekHigh":19.11,"fiftyTwoWeekLow":3.91,"fiftyTwoWeekRange":"3.91 - 19.11","fiftyDayAverage":14.46,"twoHundredDayAverage":13.35,"beta":1.91,"enterpriseValue":1260750080,"forwardPE":-5.1,"priceToBook":3.8,"priceToSales":37.34,"enterpriseToRevenue":40.19,"enterpriseToEbitda":-5.23,"pegRatio":0,"ebitda":-241124992,"ebitdaMargin":0,"freeCashflow":-148239872,"operatingCashflow":-240110000,"totalDebt":17621000,"debtToEquity":46.8,"currentRatio":8.88,"returnOnAssets":-38.9,"returnOnEquity":-72.2,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":37.42,"targetHighPrice":68,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.7,"institutionHeldPercent":104.2,"sharesOutstanding":83431950,"floatShares":65599658,"sharesShort":12478689,"shortRatio":6.52,"shortPercentOfFloat":15,"epsTrailing":-3.17,"epsForward":-2.74,"revenuePerShare":0.43,"bookValue":3.7,"officers":[{"age":66,"name":"Dr. Jay S. Duker M.D.","title":"President, CEO & Director"},{"age":60,"name":"Mr. George O. Elston CPA","title":"Executive VP & CFO"},{"age":42,"name":"Dr. Ramiro  Ribeiro M.D., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Marcia  Sellos-Moura Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Ron I. Honig Esq.","title":"Chief Legal Officer & Company Secretary"},{"age":null,"name":"Ms. Jennifer  Leonard","title":"Chief People Officer & Senior VP of  IT"},{"age":57,"name":"Mr. David Scott Jones M.A.","title":"Senior Vice President"},{"age":null,"name":"Ms. Isabelle  Lefebvre","title":"Chief Regulatory Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://eyepoint.bio","phone":"617 926 5000"}}